The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.

Mini-Oral Presentation Details:

Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)

Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center

Session: Innovative Approaches to Key Molecular Targets

Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT

Location: Room S406 (Vista Ballroom)

Abstract Number: CT262

Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models

Presenter: John M. Maris, MD, Children’s Hospital of Philadelphia

Session: Advancing the Science of Childhood Cancers: From Bench to Bedside

Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT

Location: Room E353 C

Abstract Number: 1201

Poster Presentation Details:

Title: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma

Presenter: Michal Zimmermann, PhD, Repare Therapeutics

Session: Cell Cycle Effects of Anticancer Drugs

Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT

Location: Poster Section 17

Poster Number: 9

Abstract Number: 365

Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors

Presenter: Anne Roulston, PhD, Repare Therapeutics

Session: Kinase and Phosphatase Inhibitors 1

Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT

Location: Poster Section 21

Poster Number: 9

Abstract Number: 1734

Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools

Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics

Session: Diagnostic Biomarkers 2

Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT

Location: Poster Section 31

Poster Number: 2

Abstract Number: 717

Title: Targeting CCNE1 amplification in gastric cancer

Presenter: Sung Joo Jang, Columbia University Irving Medical Center

Session: Protein Kinases and Phosphatases as Targets for Therapy

Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT

Location: Poster Section 24

Poster Number: 4

Abstract Number: 6942

A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session.

About Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

Contacts

Investor Relations & Media Contact:

Matthew DeYoung

Investor Relations and Media

Argot Partners

investors@reparerx.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.